# Efficacy and Safety of 500mg of Fulvestrant

> **NCT00585507** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00585507
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2004-04
- **Primary completion:** 2026-03-15
- **Final completion:** 2026-03-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00585507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00585507, "Efficacy and Safety of 500mg of Fulvestrant". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00585507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*